First report on molecular docking analysis and drug resistance substitutions to approved HCV NS5A and NS5B inhibitors amongst Iranian patients

Table 10 The list of amino acid residues involved in the interactions between NS5A, NS5B, and HCV inhibitors

Proteins	HCV inhibitors
Proteins	Daclatasvir	Elbasvir	Ledipasvir	Ombitasvir	Dasabuvir	Sofosbuvir
NS5A 1a	TRP9 PRO35 PHE36 ARG78 TRP84	GLU181 TYR129 SER186 GLY185	PRO192 GLU193 TYR129 THR210 THR213 ALA214	HIS150 TYR182 GLN187 TYR129 PRO194 PHE127 ARG204
NS5A 1a (Mutant GLU181)	–	GLU327 ASP292	–	–
NS5A 3a	TRP9 PRO35 PHE36 ARG78 TRP84	GLU181 TYR129 SER186 GLY185	PRO192 GLU193 TYR129 ARG122 THR210 THR213 ALA214	HIS150 TYR182 GLN187 TYR129 PRO194 PHE127 ARG204
NS5B 1a					GLU202 ARG591 ARG465 LEU545 LEU547	HIS467 GLY468 ARG591 ARG465 LEU547
NS5B 3a					MET217 LYS216 ARG213 PRO199 GLU212 GLN209 TYR205	ALA26 ARG411 HIS412 PRO414 HIS105 PRO104

ISSN: 1471-230X